Down-regulation of lymphocyte CD4 antigen expression by administration of anti-CD4 monoclonal antibody.

@article{Morel1992DownregulationOL,
  title={Down-regulation of lymphocyte CD4 antigen expression by administration of anti-CD4 monoclonal antibody.},
  author={Penelope A. Morel and Jean François Nicolas and John Wijdenes and Jean Pierre Revillard},
  journal={Clinical immunology and immunopathology},
  year={1992},
  volume={64 3},
  pages={
          248-53
        }
}
Modulation of surface CD4 antigen expression was assessed by flow cytometry after calibration with 125I-labeled anti-CD4 monoclonal antibodies (mAbs). Three patients with severe psoriasis treated with BB14 (anti-CD4 mouse IgG1) and five patients with rheumatoid arthritis treated with BL4 (anti-CD4 mouse IgG2a) were analyzed for sequential changes in surface CD4 expression on CD4+ blood lymphocytes. Anti-CD4 mAb treatment induced a decrease of 50 to 80% of CD4 expression, with slow and partial… Expand
21 Citations
Down-regulation of cell surface CD4 molecule expression induced by anti-CD4 antibodies in human T lymphocytes.
TLDR
It was concluded that down-regulation of CD4 surface expression induced by anti-CD4 mAb concerned only a part of CD2 and CD3 molecules and was associated with a decreased synthesis, likely to reflect exhaustion of the intracytoplasmic recycling pool ofCD4 molecules. Expand
Internalization and degradation of anti-CD4 monoclonal antibodies bound to human peripheral blood lymphocytes.
TLDR
The fate of anti-CD4 monoclonal antibodies (mAbs) after their interaction with CD4 protein on the surface of peripheral blood lymphocytes (PBL) is investigated and it was shown that the amount of surface-bound mAb decreased rapidly when cells were incubated at 37 degrees C, but not at 4 degrees C. Expand
The effect of anti-CD4 monoclonal antibody treatment on immunopathological changes in psoriatic skin.
TLDR
Clinical improvement of psoriasis by anti-CD4 MoAb therapy paralleled a decrease in epidermal T cells, and a down-regulation of keratinocyte activation markers (ICAM-1 and HLA-DR). Expand
Current Concepts in the Treatment of Autoimmune Diseases with Monoclonal Antibodies
TLDR
Randomised studies on a large scale are now needed to determine when mAbs should be used during the course of autoimmune disease, and which patients will benefit from this new therapy. Expand
CD4 monoclonal antibody administration in atopic dermatitis.
TLDR
Although CD4 mAb infusion may be potentially useful in the treatment of AD, the risk of aggravating the Th1/Th2 imbalance in AD should be considered in the design of future protocols. Expand
Clonal deletion and clonal anergy mediated by antibodies to the human CD4 protein
TLDR
The effect of anti-CD4 mAbs on in vitro responses of normal peripheral blood lymphocytes to various stimuli, including allogeneic B cells in mixed lymphocyte cultures (MLC) and the superantigen staphylococcal enterotoxin B (SEB) is re-examined. Expand
IMMUNOINTERVENTION IN PSORIASIS WITH ANTI–CD4 ANTIBODIES
TLDR
It is suggested that therapies which are efficient in the treatment of chronic inflammatory and autoimmune dermatoses may be considered as immunosuppressive treatments that are able to block T cell activation. Expand
CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study.
TLDR
This study shows the moderate potential efficacy of treatment of patients with Crohn's disease using a depleting chimeric monoclonal anti-CD4 antibody. Expand
The immunopathology of psoriasis.
  • J. Barker
  • Medicine
  • Bailliere's clinical rheumatology
  • 1994
TLDR
Present evidence strongly suggests that psoriasis is an immunologically mediated disease and that both cyclosporin A and FK506 are effective therapies and evidence suggests that anti-CD4 antibodies may be of great value. Expand
MECHANISMS INVOLVED IN ANTITHYMOCYTE GLOBULIN IMMUNOSUPPRESSIVE ACTIVITY IN A NONHUMAN PRIMATE MODEL 1
TLDR
The results indicate that T-cell depletion is achieved rapidly and primarily in peripheral lymphoid tissues at high ATG dosage, and short ATG treatments could therefore be clinically evaluated when major peripheral T- cell depletion is required. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 31 REFERENCES
Stimulation and proliferation of CD4+ peripheral blood T lymphocytes induced by an anti‐CD4 monoclonal antibody
TLDR
It is shown that human CD4+ lymphocytes can be activated by exposure to the anti‐CD4 monoclonal antibody (mAb) B66, and results clearly indicate that cross‐linking of surface CD4 molecules with appropriate antibodies can fully activate CD4 + lymphocytes. Expand
Cell surface comodulation of CD4 and T cell receptor by anti-CD4 monoclonal antibody.
TLDR
In the presence of anti-CD4 mAb, CD4 is functionally associated with the CD3/TCR complex, and that this association is dependent upon the activity of intracellular mediators. Expand
Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. Immunosuppressive effects and human anti-mouse responses.
TLDR
It was found that in vivo anti-T cell mAb infusions specifically suppress in vitro measurements of the human immune response, and repeated administration of these reagents in more chronic diseases can result in anti-Id-like antibodies that block binding of theAnti-Tcell mAb to the T cell surface. Expand
Antigenic modulation induced by four monoclonal antibodies adsorbed on gold particles (specificity anti-CD4, anti-CD5, anti-CD7, and anti-150-kDa antigen): relationship between modulation and cytotoxic activity of immunotoxins.
TLDR
The antibody-induced antigenic modulation of CD4, CD5, CD7, and 150-kDa antigens present on cells of the CCRF-CEM human T line suggested that receptor-mediated endocytosis via coated pits, along with an abundant occurrence of the antigen-MoAb complex within the endosomal complex, could correspond to the best set of conditions for the transfer of the toxin moiety of the immunotoxin to the cytosol. Expand
Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody.
TLDR
Treatment with monoclonal antibodies against the CD4 antigen leads to immunomodulation which results in clinical benefits, at least during initial observation periods (up to 6 months postinfusion), however, it remains to be determined whether long-term remission can be induced with this therapeutic approach. Expand
Comodulation of CD3 and CD4. Evidence for a specific association between CD4 and approximately 5% of the CD3:T cell receptor complexes on helper T lymphocytes.
TLDR
It is suggested that approximately 5% of the CD3:T cell receptor complexes on helper T lymphocytes are specifically associated with CD4, and that an average of two CD4 molecules associate with each CD3; T cell receptor complex. Expand
CD4-T-cell antigen receptor complexes on human leukemia T cells.
  • R. Chuck, C. Cantor, D. Tse
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1990
TLDR
To study multimolecular assemblies on the plasma membrane, a flow cytometric method for detecting singlet-singlet energy transfer between fluorescein isothiocyanate (FITC)- and tetramethylrhodamine isotho-conjugated monoclonal antibodies as sensitized TRITC emission on intact, single cells is developed. Expand
Inhibition of CD4+ T cell activation and adhesion by peptides derived from the gp160.
TLDR
This study shows that gp160 is also able to inhibit the Ag-independent adhesion of CD4+ T cells to B cells as anti-CD4 antibodies do, and suggests that binding of part of this region to CD4 can alter T cell proliferation and adhesion. Expand
Enhancing effects of monocytes on modulation of a lymphocyte membrane antigen.
TLDR
The finding that leukemic cells from patients with CLL undergo modulation of the T65 antigen to a much lower degree in vitro than observed in vivo, suggests that monocytes or the reticuloendothelial system may augment antigenic modulation in vivo. Expand
Anti-CD4 monoclonal antibody administration in renal transplanted patients.
Administration of anti-CD4 antibodies in rodents was shown to prevent or to reverse spontaneous or experimentally induced autoimmune diseases and to delay organ or skin allograft rejection. SomeExpand
...
1
2
3
4
...